Hoping to tackle the absolutely brutal Huntington’s disease, Roche inked a licensing pact with Ionis back in 2017 for a novel antisense therapy targeting a protein implicated in the disease. Now, after riding out earlier safety red flags, Roche is calling a late-stage study quits on a data committee’s orders.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,